Psychopharmacology and Psychiatry Updates

Esketamine: Postmarketing Safety Concerns

10.09.2021 - By Psychopharmacology InstitutePlay

Download our free app to listen on your phone

Download on the App StoreGet it on Google Play

How risky is esketamine? In this episode, we examine the safety of esketamine using postmarketing data that have been reported since the drug was approved and released. Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D. Learn more about our memberships here Earn 0.5 CMEs: Quick Take Vol. 27 Postmarketing Safety Concerns With Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System  

More episodes from Psychopharmacology and Psychiatry Updates